Worth Venture Partners’s Adverum Biotechnologies ADVM Stock Holding History

Worth Venture Partners’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-78,435	Closed	-$590K	–	65
2023 Q4	$590K	Buy	78,435 +45,268	+136%	+$413K	0.32%	71
2023 Q3	$498K	Sell	33,167 -3,901	-11%	-$70K	0.3%	81
2023 Q2	$589K	Buy	37,068 +7,212	+24%	+$75.8K	0.32%	71
2023 Q1	$214K	Hold	29,856	–	–	0.1%	125
2022 Q4	$173K	Hold	29,856	–	–	0.1%	116
2022 Q3	$284K	Buy	29,856 +4,976	+20%	+$65.4K	0.17%	95
2022 Q2	$425K	Buy	+24,880	New	+$261K	0.25%	83

Other funds holding ADVM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Worth Venture Partners's ADVM Position: Q1 2024 in Review

Worth Venture Partners sold out of Adverum Biotechnologies (ADVM) in Q1 2024, closing a stake of 78,435 shares — an estimated $590K sold.

Worth Venture Partners first reported a position in ADVM in Q2 2022 and held it in 7 quarters. The position peaked at $590K in Q4 2023. 61 funds tracked by Wall St. Rank hold ADVM as of Q1 2024.

Worth Venture Partners reported no remaining Adverum Biotechnologies position as of Q1 2024 after selling out during the quarter.
Worth Venture Partners sold 78,435 Adverum Biotechnologies shares in Q1 2024, an estimated $590K.
Worth Venture Partners first reported a position in Adverum Biotechnologies in Q2 2022 and held it in 7 quarters.
Worth Venture Partners's Adverum Biotechnologies position peaked at $590K in Q4 2023.
61 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2024.

Based on Worth Venture Partners's 13F filing for Q1 2024, filed 13 May 2024.